New York, New York (PRWEB) December 12, 2013
Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) , including many that allege use of the antipsychotic drug caused some men and young boys to develop gynecomastia, or male breast growth, continue to move forward in a consolidated litigation underway in the Philadelphia Court of Common Pleas in Pennsylvania. According to a brief filed earlier this month, Plaintiffs have asked the court to reject a request from Johnson & Johnson to allow some Risperdal clinical studies to remain sealed. Among other things, Plaintiffs assert that the risks allegedly associated with Risperdal are too great to keep the documents from the public. (In Re: Risperdal Litigation, Case Number 100300296)
According to court records, the documents in question were originally sealed by the Court in 2011. In November, Johnson & Johnson filed a motion with the Court asking that the Risperdal studies remain sealed, asserting that they were intended to be used by researchers and regulators, and were never meant to be circulated to the general public.
“Our Firm has heard from numerous patients concerned about the potential link between Risperdal and gynecomastia. We will be monitoring this issue very closely, and look forward to the Court’s decision,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently evaluating Risperdal lawsuits on behalf of men and boys who may developed gynecomastia allegedly due to their use of the drug.
Court documents indicate that 275 lawsuits, including many that allege a connection between the use of Risperdal and gynecomastia, are pending in the Pennsylvania litigation. All of the complaints accuse Johnson & Johnson of concealing serious Risperdal side effects, including male breast growth. The lawsuits also allege that the drug was improperly marketed for off-label uses, including for use in children.
The U.S. Department of Justice announced on November 4th that it had reached a settlement with Johnson & Johnson regarding the improper marketing of Risperdal and other drugs. According to a statement issued by federal prosecutors, the $2.2 billion accord was one of the largest health care settlements in history. Among other things, the Justice Department had alleged that Risperdal was illegally marketed for use in children prior to the approval of pediatric uses in 2006. The government had also alleged that side effects associated with the drug were concealed, including an association between Risperdal and male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and young boys who developed gynecomastia while taking Risperdal may be entitled to compensation for their injury related damages. To learn more about the potential association between Risperdal and male breast growth, please visit Bernstein Liebhard LLP’s website. For a free Risperdal lawsuit review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-male-breasts/prweb11419621.htm.
Copyright©2012 Vocus, Inc.
All rights reserved